



13 March 2014

SIRION Biotech's adenovirus platform technology allows for overexpression of BACH2: BACH2 plays role in type 1 Diabetes by regulating pancreatic β -cell apoptosis

American Diabetes Association posts publication presenting clarification on the BACH2 mechanism to contribute to diabetes

Munich, SIRION Biotech provided successfully recombinant adenovirus containing the human BACH2 mRNA (GenBank: NM_021813) in a study meant to clarify an unexpected and relevant mechanism by which BACH2 may contribute to diabetes. The human BACH2 coding region was amplified by PCR from cDNA clone BC166613 purchased from Source Bioscience (Berlin, Germany). The BACH2 coding region was then transferred via recombination into plasmid pADCMV-DEST containing the genome of a replication deficient Ad5-based vector deleted in E1/E3 genes. The results by this study group around leading European scientists from Belgium, Italy & Spain is now being published by the American Diabetes Association, find link to publication under http://www.sirion-biotech.com/application_notes.html.

About SIRION Biotech www.SIRION-Biotech.com

SIRION Biotech started in Munich in 2007 with the idea of enabling novel cell models closer to reality than ever before. This required the assembly of an all-encompassing, novel viral vector platform. Both, designing de novo viral vectors and the subsequent creation of custom cell models will pave the way for superior compound development in the life sciences. SIRION's technologies have been validated in over 300 single projects with more than 100 academic and industrial partners. As a result, cell models for drug discovery and development have become highly reliable, as have the use of new viral vectors in gene therapy and vaccine studies.

Contact SIRION:

SIRION BIOTECH GmbH

Dr. Christian Thirion

Am Klopferspitz 19

D-82152 Martinsried

Tel.: +49-89-700 961 99-15

eMail: Thirion@SIRION-Biotech.com

www.SIRION-Biotech.com